XXXX response variability: impact of genetic polymorphism and platelet biomarkers for predicting adverse outcomes poststenting.

@entity1 @entity583 @entity4433 @entity20417 @entity1423 @entity1397 @entity72060 @entity951 @entity299 @entity453 @entity204 @entity715
The aim of this study was to triage platelet reactivity and adverse vascular outcomes after dual antiplatelet therapy due to percutaneous coronary intervention (PCI) dependent on @entity4433 *2 and @entity4433 *3 genotypes in @entity1 with @entity453 . Fifty-five @entity1 with @entity453 were studied serially pre-PCI and post-PCI. Platelet reactivity was assessed by conventional light transmission aggregometry, VerifyNow Analyzer, and thromboelastography with platelet mapping. Genetic testing was performed with allele-specific real-time polymerase chain reaction. Adverse events included @entity204 , acute @entity583 , repeated PCI, definite stent @entity715 , and @entity951 . The common genotype (GG) was found in 39 @entity1 , heterozygous polymorphism @entity4433 (GA) @entity20417 allele was detected in 14 @entity1 , and the rare homozygous polymorphism @entity4433 (AA) @entity20417 allele was exhibited in 2 @entity1 . There were no @entity4433 *3 ( @entity72060 ) carriers among index @entity1 . The platelet reactivity was higher in @entity1 with heterozygous and homozygous carriers compared with GG genotype. The largest differences were observed among GG, GA, and AA genotypes, which correlated with the average values of @entity1423 (P = 0.02). There was a significant link between adverse events and high platelet reactivity assessed by light transmission aggregometry (P = 0.002). We found a trend between different genotype and VerifyNow readings (P = 0.057); moreover, their cumulative impact on adverse events was significant (P = 0.041). Platelet reactivity is higher in @entity1 with heterozygous and homozygous carriers of @entity4433 *2 versus common genotype and may predict an increased risk of @entity1397 response variability and/or experiencing adverse @entity299 .
